Replimune (REPL) Capital Expenditures (2017 - 2026)
Replimune (REPL) reported Capital Expenditures of $80000.0 for Q1 2026, up 157.97% on a YoY basis from $31011.2 in Q1 2025, and up 145.2% sequentially from -$177000.0 in Q4 2025.
Replimune (REPL) Capital Expenditures (2017 - 2026) Analysis & Trends
Replimune (REPL) has 10 years of Capital Expenditures data on file, last reported at $80000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 157.97% year-over-year to $80000.0; the trailing twelve-month figure through Mar 2026 stood at $80000.0 (down 53.22% YoY), and the FY2026 full-year result was $80000.0, down 53.22% from the prior year.
- Capital Expenditures rose to $80000.0 in Q1 2026, from -$177000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $5.7 million in Q1 2024 to a low of -$3.4 million in Q4 2024.
- A 5-year average of $308647.1 and a median of $80000.0 in 2026 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 770.1% in 2024, while the deepest fall reached 2395.65% in 2024.
- Tracing REPL's Capital Expenditures over 5 years: stood at $555000.0 in 2022, then sank by 124.86% to -$138000.0 in 2023, then sank by 2395.65% to -$3.4 million in 2024, then jumped by 94.86% to -$177000.0 in 2025, then surged by 145.2% to $80000.0 in 2026.
- Business Quant data shows REPL's Capital Expenditures at $80000.0 in Q1 2026, -$177000.0 in Q4 2025, and -$2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | 80,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80,000.00 |
| Mar 31, 2026 | 80,000.00 |
| Dec 31, 2025 | -177,000.00 |
| Dec 31, 2025 | -177,000.00 |
| Sep 30, 2025 | -2.56 Mn |
| Sep 30, 2025 | -2.56 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Mar 31, 2025 | -138,000.00 |
| Mar 31, 2025 | -138,000.00 |
| Dec 31, 2024 | -3.44 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 1.67 Mn |
| Jun 30, 2024 | 1.67 Mn |
| Mar 31, 2024 | 5.66 Mn |
| Mar 31, 2024 | 5.66 Mn |
| Dec 31, 2023 | -138,000.00 |
| Dec 31, 2023 | -138,000.00 |